MARKET

ATHA

ATHA

Athira Pharma, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.44
+0.17
+0.84%
Opening 13:56 01/22 EST
OPEN
20.16
PREV CLOSE
20.27
HIGH
21.45
LOW
20.14
VOLUME
740.49K
TURNOVER
--
52 WEEK HIGH
34.79
52 WEEK LOW
15.79
MARKET CAP
588.97M
P/E (TTM)
-101.7422
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CLSN, RIOT, POLA and MARA among midday movers
Gainers: Vinco Ventures (BBIG) +312%.ADiTx Therapeutics (ADTX) +90%.Qutoutiao (QTT) +65%.Ideal Power (IPWR) +51%.BiondVax Pharmaceuticals (BVXV) +39%.Celsion (CLSN) +34%.Polar Power (POLA) +33%.Addex Therapeutics (ADXN) +28%.Pioneer Power Solutions (PPSI) ...
Seekingalpha · 1d ago
DJ Athira Pharma Shares Drop 13% After Public Offering Prices
Dow Jones · 1d ago
MARA, RIOT, FCEL among premarket losers
Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group MARA -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain RIOT -11% as Bitcoin crumbles despite good news rolls in.Foresight...
Seekingalpha · 1d ago
Athira Pharma Priced 4M Share Public Offering of Common Stock @$22.50/Share
Athira Pharma, Inc., (NASDAQ: ATHA) announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a public offering price of $22.50 per share. All of the shares of common stock are being offered by Athira.
Benzinga · 1d ago
Athira Pharma prices equity offering at $22.50
Athira Pharma (ATHA) has priced its public offering of 4M common shares at $22.50/share, for expected gross proceeds of $90M.Underwriters' over-allotment is an additional 600K shares.Closing date is January 25.Shares down
Seekingalpha · 1d ago
Athira Pharma Prices $90 Million Public Offering
MT Newswires · 1d ago
*DJ Goldman Sachs, Jefferies, Stifel Acting as Bookrunning Managers for Athira Pharma Offering >ATHA
Dow Jones · 1d ago
*DJ Athira Pharma Grants Underwriters 30-Day Option to Buy Up to 600,000 Additional Shares >ATHA
Dow Jones · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHA. Analyze the recent business situations of Athira Pharma, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHA stock price target is 44.25 with a high estimate of 51.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 21.66M
% Owned: 75.16%
Shares Outstanding: 28.81M
TypeInstitutionsShares
Increased
0
0
New
54
21.66M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.84%
Pharmaceuticals & Medical Research
+0.79%
Key Executives
President/Chief Executive Officer
Leen Kawas
Chief Financial Officer/Secretary/Primary Contact
Glenn Mileson
Chief Operating Officer
Mark Litton
General Counsel
Christina Thomson
Other
Han Moebius
Director
Kelly Romano
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATHA
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
More

Webull offers kinds of Athira Pharma Inc stock information, including NASDAQ:ATHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHA stock methods without spending real money on the virtual paper trading platform.